Evenity (Romosozumab): Legal and Patent Challenges

FDA Approval History and Initial Regulatory Hurdles

Romosozumab received FDA approval on April 9, 2019, but the path to that date was anything but smooth. The agency had issued a Complete Response Letter (CRL) in July 2017, requesting additional safety data after reviewing cardiovascular signals in the ARCH trial [1]. That two-year delay cost Amgen and UCB significant market exclusivity runway and set the stage for ongoing label disputes.

The original Biologics License Application (BLA) relied primarily on the FRAME trial (N=7,180), which compared romosozumab to placebo in postmenopausal women with osteoporosis. FRAME showed a 73% reduction in new vertebral fractures at 12 months (0.5% vs. 1.8%, P<0.001) [2]. The results were striking. But the FDA's concern centered on ARCH (N=4,093), the active-comparator trial that tested romosozumab against alendronate [1]. ARCH demonstrated superior fracture reduction with romosozumab, yet also revealed a higher incidence of adjudicated major adverse cardiac events (MACE): 2.5% in the romosozumab group vs. 1.9% in the alendronate group over 12 months of treatment [1].

The FDA's Bone, Reproductive, and Urologic Drugs Advisory Committee voted 18-1 in January 2019 in favor of approval, but with the explicit recommendation of a boxed warning [3]. Dr. Kendall Moseley, an endocrinologist at Johns Hopkins, commented at the time: "The benefit for women at very high fracture risk is real, but clinicians need a clear signal that cardiovascular history matters in prescribing decisions" [3]. That boxed warning became the single most consequential regulatory constraint on the drug's commercial trajectory.

The Patent Field: What Amgen and UCB Hold

Amgen's intellectual property portfolio around romosozumab is broad and deliberately layered. The Orange Book lists several patents tied to the Evenity BLA, covering the antibody composition, specific formulations, and methods of treatment [4].

The foundational composition-of-matter patent, US 7,592,429, covers anti-sclerostin antibodies with specific binding characteristics. This is the patent that matters most. Composition-of-matter patents provide the widest protection because they cover the molecule itself, not just how it is made or used. According to FDA Orange Book records, this patent's listed expiration falls in the 2026-2027 window [4]. A second key patent, US 7,879,322, covers pharmaceutical compositions containing the antibody at specific concentrations and pH ranges, extending protection into the late 2020s [4].

Method-of-use patents add another defensive ring. US 8,017,120 claims methods of increasing bone mineral density using anti-sclerostin antibodies at defined doses, while US 9,505,832 covers the 12-dose monthly regimen that became the approved dosing schedule [4]. These method patents typically expire later than composition patents and can be wielded against biosimilar applicants who must demonstrate that their product is used for the same indications.

Amgen has a documented history of aggressive patent defense. The company's litigation over denosumab (Prolia/Xgeva) against Sandoz and its disputes with Sanofi/Regeneron over PCSK9 inhibitor patents offer a preview of the strategy likely to be deployed for romosozumab [5]. In the PCSK9 case, Amgen initially won a jury verdict asserting broad genus claims, though the Federal Circuit later vacated and remanded the decision, narrowing the scope of antibody patent protection across the industry [5].

The Boxed Warning: Clinical Liability and Legal Exposure

The cardiovascular boxed warning is not just a labeling issue. It is a legal fulcrum. The warning states that romosozumab "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and should not be used in patients who have had a myocardial infarction or stroke within the preceding year [6].

This warning creates two distinct legal vectors. First, product liability: if a patient with known cardiovascular risk factors suffers a cardiac event while on romosozumab, the prescribing decision and the adequacy of the manufacturer's warnings become litigable questions. Second, off-label promotion risk: any marketing that minimizes or de-emphasizes the boxed warning could expose Amgen and UCB to False Claims Act liability or FDA enforcement action.

The ARCH trial data driving the warning showed 50 MACE events in the romosozumab-to-alendronate group vs. 38 in the alendronate-to-romosozumab group during the first 12 months [1]. The absolute difference was modest. But the FDA's boxed warning threshold is not purely statistical; it reflects the agency's judgment about the severity of the potential harm relative to the benefit. Dr. Clifford Rosen, a senior scientist at Maine Medical Center Research Institute who served on the advisory committee, stated: "When you have a signal for cardiovascular death in a population that already has competing mortality risks from hip fracture, the labeling has to be unambiguous" [3].

As of May 2026, no major class-action litigation against Amgen specifically for romosozumab cardiovascular injuries has reached federal multidistrict litigation (MDL) status. Individual lawsuits and pre-litigation claims have been filed, but the volume remains low compared to drugs like Vioxx or Avandia, which faced similar cardiovascular safety signals [7]. The 12-month treatment limitation built into the label may be functioning as a natural risk mitigator, reducing cumulative exposure.

Post-Market Surveillance and Label Evolution

The FDA required Amgen to conduct post-marketing studies as a condition of approval, including a study to further evaluate cardiovascular risk in a broader population [6]. The EMA's Committee for Medicinal Products for Human Use (CHMP) imposed similar requirements when it approved romosozumab in December 2019, though the European label carries somewhat different cardiovascular contraindications [8].

Post-market pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) through Q1 2026 show that cardiovascular events remain the most frequently reported serious adverse event category for romosozumab [9]. Interpretation of FAERS data requires caution because reporting is voluntary, denominators are unknown, and the population taking romosozumab is already at elevated baseline cardiovascular risk due to age and comorbidities. A 2023 pharmacovigilance study published in the Journal of Bone and Mineral Research analyzed FAERS data and found a disproportionality signal for cardiac events (reporting odds ratio 1.89, 95% CI 1.62-2.21) but noted that confounding by indication could not be excluded [10].

The label has undergone minor updates since initial approval, including clarifications to the Warnings and Precautions section regarding hypocalcemia management and injection-site reactions [6]. No new indications have been approved. Amgen has not pursued a male osteoporosis indication for romosozumab in the U.S., though the EMA label covers men at increased fracture risk [8]. This divergence between the FDA and EMA labels creates a regulatory asymmetry that affects global commercial strategy and could influence future patent extension calculations.

Biosimilar Pathway and Competitive Threats

Romosozumab is a biologic, not a small molecule. Biosimilar competition therefore proceeds under the Biologics Price Competition and Innovation Act (BPCIA), which grants 12 years of data exclusivity from the date of first licensure [11]. For romosozumab, this 12-year clock started on April 9, 2019, placing the earliest possible biosimilar approval date around April 2031, assuming no patent barriers beyond that date.

The 12-year exclusivity is a floor, not a ceiling. Patent thickets can extend effective exclusivity well beyond 2031. The BPCIA includes a complex "patent dance" process in which the biosimilar applicant and the reference product sponsor exchange patent information and negotiate which patents to litigate before launch [11]. Amgen's experience with the denosumab biosimilar pathway (where the company filed suit against multiple biosimilar developers) suggests the company will use every available procedural tool to delay romosozumab biosimilar entry [5].

No biosimilar application for romosozumab has been publicly filed with the FDA as of May 2026. Samsung Bioepis, Biocon, and Celltrion have been reported in industry analyses as having early-stage development programs for anti-sclerostin biosimilars, though none have disclosed Phase III clinical data [12]. The technical complexity of manufacturing a monoclonal antibody with the specific binding affinity required for sclerostin inhibition adds development time and cost that small-molecule generics do not face.

From a market perspective, romosozumab generated approximately $1.2 billion in global net sales for Amgen in 2025, a figure that has grown steadily since launch [13]. The drug's position as the only approved sclerostin inhibitor gives it first-mover advantage, but also means any biosimilar entrant would face a relatively small addressable market compared to biosimilars of adalimumab or trastuzumab.

International Regulatory Divergence

The regulatory field for romosozumab varies meaningfully across jurisdictions, and these differences have legal implications for patent strategy and market access.

In the European Union, the EMA approved romosozumab in December 2019 with a contraindication (rather than a boxed warning, which is a U.S.-specific label format) for patients with a history of myocardial infarction or stroke [8]. The EMA label also covers treatment of osteoporosis in men at increased fracture risk, an indication the FDA has not granted [8]. Japan approved romosozumab in January 2019, actually ahead of the FDA, through the Pharmaceuticals and Medical Devices Agency (PMDA), with its own set of post-marketing requirements [14].

These regulatory divergences matter for patent strategy because Amgen must maintain separate patent portfolios and litigation postures in each jurisdiction. A European patent invalidation would not directly affect U.S. Patent rights, but it could accelerate biosimilar development by allowing manufacturers to gain clinical and manufacturing experience in markets with weaker patent protection. The Unified Patent Court (UPC), which began operations in June 2023, introduces a new variable: a single UPC ruling on a European patent's validity now applies across most EU member states, raising the stakes of any European challenge [15].

In Canada, Health Canada approved romosozumab in June 2022 with cardiovascular warnings aligned more closely with the EMA's contraindication approach than the FDA's boxed warning format [16]. Australia's Therapeutic Goods Administration (TGA) followed with approval in 2020 [17]. Each jurisdiction's approach to the cardiovascular safety signal reflects local regulatory culture and risk tolerance, but all converge on the same core concern identified in the ARCH trial.

What Prescribers and Patients Should Know

The legal and patent complexities surrounding romosozumab translate into practical clinical realities. The drug remains available only as a brand-name product with no biosimilar alternative expected before 2031 at the earliest. Its annual cost of approximately $22,000-$24,000 places significant pressure on insurance coverage decisions, particularly given the boxed warning that narrows the eligible patient population [6].

For patients at very high fracture risk (defined by the Endocrine Society as those with a recent fracture, a T-score of -3.0 or below, or a high FRAX probability), romosozumab remains a first-line anabolic option with strong trial-based evidence of fracture reduction [18]. The FRAME trial documented a 73% reduction in vertebral fractures at 12 months, and ARCH showed a 48% reduction in new vertebral fractures compared with alendronate at 24 months [1][2]. These numbers are among the largest fracture risk reductions demonstrated in any osteoporosis trial.

Prescribers should document cardiovascular risk assessment before initiating romosozumab, both for clinical appropriateness and for medicolegal defensibility. A baseline ECG, blood pressure measurement, and review of cardiac history are minimum expectations under the current label [6]. The 12-dose treatment course should be followed by an antiresorptive agent (typically denosumab or a bisphosphonate) to maintain the bone density gains achieved during the anabolic window.